Relevant bibliographies by topics / Acute Leukaemia

Academic literature on the topic 'Acute Leukaemia'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Acute Leukaemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Acute Leukaemia"

1

Sarrou, Evgenia, Laura Richmond, Ruaidhrí J. Carmody, Brenda Gibson, and Karen Keeshan. "CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis." International Journal of Molecular Sciences 21, no. 12 (June 15, 2020): 4266. http://dx.doi.org/10.3390/ijms21124266.

Full text
Abstract:
Chromosomal rearrangements of the mixed lineage leukaemia (MLL, also known as KMT2A) gene on chromosome 11q23 are amongst the most common genetic abnormalities observed in human acute leukaemias. MLL rearrangements (MLLr) are the most common cytogenetic abnormalities in infant and childhood acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL) and do not normally acquire secondary mutations compared to other leukaemias. To model these leukaemias, we have used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing to induce MLL-AF9 (MA9) chromosomal rearrangements in murine hematopoietic stem and progenitor cell lines and primary cells. By utilizing a dual-single guide RNA (sgRNA) approach targeting the breakpoint cluster region of murine Mll and Af9 equivalent to that in human MA9 rearrangements, we show efficient de novo generation of MA9 fusion product at the DNA and RNA levels in the bulk population. The leukaemic features of MA9-induced disease were observed including increased clonogenicity, enrichment of c-Kit-positive leukaemic stem cells and increased MA9 target gene expression. This approach provided a rapid and reliable means of de novo generation of Mll-Af9 genetic rearrangements in murine haematopoietic stem and progenitor cells (HSPCs), using CRISPR/Cas9 technology to produce a cellular model of MA9 leukaemias which faithfully reproduces many features of the human disease in vitro.
APA, Harvard, Vancouver, ISO, and other styles
2

Kuzmits, Rudolf, Paul Aiginger, Matthias M. Müller, Günter Steurer, and Werner Linkesch. "Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells." Clinical Science 71, no. 1 (July 1, 1986): 81–88. http://dx.doi.org/10.1042/cs0710081.

Full text
Abstract:
1. A short-term test in vitro is described, which can be used to detect resistance to cytostatic agents in leukaemic cells. Leukaemic cell suspensions were incubated with cytostatic agents and the resulting intracellular ATP concentrations were measured by a bioluminescence ATP assay. 2. There was a clear dose-effect relationship in acute leukaemia and chronic lymphocytic leukaemia cells for drugs used in the treatment of leukaemias. A good correlation was found between the ATP content of leukaemic cells and cell viability as determined by the trypan blue dye exclusion test. 3. Preliminary individual clinical correlations suggest a correlation between the chemosensitivity in vitro and the response patterns in vivo in leukaemia patients. This simple, fast and sensitive method may have application for determination of drug-induced cytotoxicity in leukaemic cells in vitro.
APA, Harvard, Vancouver, ISO, and other styles
3

Skarsgård, Lisa Stenman, Mattias K. Andersson, Marta Persson, Ann-Cathrine Larsen, Sarah E. Coupland, Göran Stenman, and Steffen Heegaard. "Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations." BMJ Open Ophthalmology 4, no. 1 (October 2019): e000362. http://dx.doi.org/10.1136/bmjophth-2019-000362.

Full text
Abstract:
ObjectiveTo describe the clinicopathological and genomic features of nine patients with primary and secondary orbital/ocular manifestations of leukaemia.MethodsAll orbital/ocular leukaemic specimens from 1980 to 2009 were collected from the Danish Register of Pathology. In six cases, medical records and formalin-fixed, paraffin-embedded blocks were available. Three cases from the Department of Pathology, Royal Liverpool University Hospital, were also included. Immunophenotypes and MYB oncoprotein expression were ascertained by immunohistochemistry. Genomic imbalances were analysed with comparative genomic hybridisation arrays and oncogene rearrangements with fluorescence in situ hybridisation.ResultsFour patients had B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) and five had acute myeloid leukaemia (AML). Two patients with BCP-ALL and one with AML had primary orbital manifestations of leukaemia. Common symptoms were proptosis, displacement of the eye, and reduced eye mobility in patients with orbital leukaemias and pain, and reduced visual acuity in patients with ocular leukaemias. All patients with primary orbital lesions were alive up to 18 years after diagnosis. All but one patient with secondary ophthalmic manifestations died of relapse/disseminated disease. ETV6 and RUNX1 were rearranged in BCP-ALL, and RUNX1 and KMT2A in AML. Genomic profiling revealed quiet genomes (0–7 aberrations/case). The MYB oncoprotein was overexpressed in the majority of cases.ConclusionsLeukaemias with and without ophthalmic manifestations have similar immunophenotypes, translocations/gene fusions and copy number alterations. Awareness of the clinical spectrum of leukaemic lesions of the eye or ocular region is important to quickly establish the correct diagnosis and commence prompt treatment.
APA, Harvard, Vancouver, ISO, and other styles
4

Nurunnabi, Md, Mosammath Khadiza Mamdu, Ayesha Siddika, Farzana Zafreen, Md Abdul Wahab, and Shahana Shermin. "Morphological and Immunophenotypic Analysis in Diagnosis of Acute Leukaemia." Delta Medical College Journal 8, no. 1 (March 31, 2022): 15–20. http://dx.doi.org/10.3329/dmcj.v8i1.58958.

Full text
Abstract:
Background: Leukaemias are neoplastic proliferations of haematopoietic stem cells and form a major proportion of haematopoietic neoplasms that are diagnosed worldwide. Objective: To differentiate between morphological and immunophenotypic analysis in the diagnosis of acute leukemia. Materials and method: This cross sectional study was conducted in the department of Haematology, Armed Forces Institute of Pathology (AFIP), Dhaka, Bangladesh from January 2008 to December 2008. Total 50 patients were included after fulfilling inclusion and exclusion criteria. Results: The total of 50 bone marrow samples from suspected cases of acute leukaemia were included in the study. Out of 50 samples, 48 cases were diagnosed as either acute myeloid leukaemia (19 or 38%) or acute lymphoblastic leukaemia (29 or 58%) and 02 (04%) cases were morphologically indistinguishable. All 50 cases were subjected to immunophenotypic study. Out of 50 cases immunophenotypically 14(28%) were acute myeloid leukaemia (AML), 32(64%) were acute lymphoblastic leukaemia (ALL), and bi-phenotypic leukaemia and acute undifferentiated leukaemia were 02(04%) each. In this study Male: Female ratio was 1.3:1. Out of 19(38%) cases of AML, 29(58%) cases of ALL and 02(04%) cases of indistinguishable diagnosed morphologically, 14(28%) were found to be AML, 32(64%) ALL, 02(04%) bi-phenotypic and 02(04%) were acute undifferentiated leukaemias on immunophenotyping respectively. Out of 29 cases identified as ALL on morphology 25(86.2%) were confirmed as ALL, 02(07%) turned out to be AML, 01(3.4%) was bi-phenotypic and 01(3.4%) was undifferentiated. Conclusion: In this study, acute lymphoblastic leukaemia was the commonest type of leukemia followed by acute myeloid leukaemia with male predominance seen in all types of leukaemia. Delta Med Col J. Jul 2020 8(1): 15-20
APA, Harvard, Vancouver, ISO, and other styles
5

Ivanovic, Mirjana, Olivera Jovicic, Jelena Mandic, Dusko Bogetic, and Marcello Maddalone. "Oral manifestations of acute leukaemia." Srpski arhiv za celokupno lekarstvo 139, no. 1-2 (2011): 103–6. http://dx.doi.org/10.2298/sarh1102103i.

Full text
Abstract:
Acute leukaemia is the most common form of chilhood cancer. The aim of this paper was to underline the importance of oral manifestations in children with acute leukaemia. The disease and its treatment can directly or indirectly affect oral health. Oral manifestations are gingival inflammation and enlargement. Leukaemic cells are capable of infiltrating the gingiva and the deeper periodontal tissues which leads to ulceration and infection of oral tissues. Gingival bleeding is a common sign in patients with leukaemia. Symptoms include local lymphadenopathy, mucous membrane Petechiae and ecchymoses. Cytotoxic drugs have direct effects like mucositis, involving atrophy, desquamation and ulceration of the mucosa, with increasing the risk for local and systemic infections. Leukaemia can directly influence dental care and dental treatment, while oral lesions may have life-threatening consequences. Knowledge and skills among dentists may also not be adequate to treat children with acute leukaemia. It is therefore imperative that all stomatologists be aware of dental problems that occur in leukaemia in order to be able to effectively carry out appropriate measures to mitigate these problems.
APA, Harvard, Vancouver, ISO, and other styles
6

Budi, Luh Putu Rihayani, Ketut Ariawati, and Sianny Herawati. "NEONATAL ACUTE MYELOID LEUKAEMIA." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 19, no. 3 (October 14, 2016): 211. http://dx.doi.org/10.24293/ijcpml.v19i3.417.

Full text
Abstract:
Acute myeloid leukaemia (AML) is a. malignant, clonally disease that involves proliferation of blasts in bone marrow, blood, or other tissue. The blasts most often show myeloid or monocytic differentiation. The incidence of AML increases with age, but when neonatal leukaemia does occur, it is paradoxically AML rather than ALL. All the signs and symptoms that present on patient with AML are caused by the infiltration of the bone marrow with leukaemic cells and resulting failure of normal haematopoiesis. Without the normal haematopoietic elements, the patient is at risk for developing life-threatening complications of anaemia, infection due to functional neutropenia, and haemorrhage due to thrombocytopenia. Organomegaly is seen in approximately half of patient with AML due to hepatic and sphlanic infiltration with leukaemic blasts. Prognosis of neonatal leukaemia is poor with the 6-month survival rate is only one third despite aggressive chemotherapy. It has higher mortality rate than any other congenital cancer. The researchers reported two of AML diagnosed cases in neonatal period. The first case, a one-day-old male was referred with respiratory distress and suspect Down syndrome with spontaneous petechiae. The second case, a 17-day-old female presented with bloody diarrhoea and history of hypothyroid. Dysmorphic face and hepatosplenomegalia were found in both of the physical examination. Their complete blood count revealed leukocytosis and thrombocytopenia. Peripheral blood smear revealed myeloblast 30% on the first case and 23% on the second case. Both immunophenotyping revealed the population of blast expressing myeloid lineage (CD33 and CD34).
APA, Harvard, Vancouver, ISO, and other styles
7

Jeong, E., H. J. Park, J. Y. Lee, and B. K. Cho. "Leukaemic macrocheilia in acute myeloblastic leukaemia." British Journal of Dermatology 151, no. 5 (November 2004): 1102. http://dx.doi.org/10.1111/j.1365-2133.2004.06242.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dachi. "Acute Leukaemias in Bauchi State, Northeastern Nigeria: Pattern of Presentations and Clinical Entities." West Africa Journal of Medicine 39, no. 5 (June 26, 2022): 497–500. http://dx.doi.org/10.55891/wajm.v39i5.122.

Full text
Abstract:
Background: Acute leukaemias are very aggressive diseases that run a rapidly fatal course if not promptly diagnosed and appropriately treated. The clinical presentations range from bone marrow failure such as anaemia, neutropenia or thrombocytopenia to features of organ infiltrations such as lymphadenopathy, splenomegaly, etc, but presentations may be non-specific. Misdiagnosis is very common with delay in diagnosis and prompt treatment being the causes of high morbidity and mortality in acute leukaemias. This study aims to determine the pattern of presentation and various clinical entities of acute leukaemias in Bauchi State, North-Eastern Nigeria. Subjects, materials and methods: This was a three year retrospective study in which records of cases of acute leukaemias diagnosed in the Haematology Department of Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH) Bauchi from the bone marrow aspiration cytology register from 1st January, 2018 to 31st December, 2020 were collected. Data on socio-demographic characteristics of the patients that include age, gender, diagnosis as well as subtypes of some of the malignancies diagnosed were also collated. The collated data were analyzed using SPSS Version 20.0. A p-value of < 0.05 was considered significant. Results: Twenty-nine cases of acute leukaemias were diagnosed during the period under review. Majority of cases had acute lymphoblastic leukaemia (ALL) 19/29 (65.5%) while acute myeloid leukaemia (AML) was seen in 10/29 (34.5%). The mean ± SD age of the patients was 22.2±9.2 years with a range 6 months to 60 years. Males constituted 75.9% (22/29) of the cases of acute leukaemias diagnosed. The male to female ratios for AML and ALL were 2:1 and 2.6:1 respectively. The mean±SD ages for AML and ALL were 27±9.2years and 17.3±11.3 years respectively. The most common form of presentation of acute leukaemia in this study is recurrent anaemia necessitating blood transfusion while proptosis and epistaxis were the least forms of presentation. Conclusion: Acute lymphoblastic leukaemia is the commonest form of acute leukaemias while recurrent anaemia is the commonest form of clinical presentations in our setting. Early referral of patients with clinical features suggestive of acute leukaemias is recommended. Author R A Dachi 1, F G Mustapha 1, M Mahdi 1, H Abbas 2
APA, Harvard, Vancouver, ISO, and other styles
9

Onoja, AM, SA Otene, AT Onoja, IN Ibrahim, A. Mke, I. Okolie, R. Okoli, et al. "Prevalence and Nature of Adult Hematological Malignancies Using Bone Marrow Aspiration Cytology in a Tertiary Health Facility: A Seven Year Retrospective Review." Western Journal of Medical and Biomedical Sciences 2, no. 1 (April 12, 2021): 39–45. http://dx.doi.org/10.46912/wjmbs.39.

Full text
Abstract:
Bone Marrow Aspiration (BMA) is a procedure that is often used to evaluate patients with haematological disorders including haematological malignancies (HMs) which account for about 6.5% of all cancers worldwide. There is paucity of data on the prevalence and pattern of HMs from BMA cytology in Nigeria. We carried out a retrospective review to determine the prevalence and distribution of HMs among adult patients who had BMA cytology at Benue State University Teaching Hospital (BSUTH) from June 2012 to July 2019. A total of 158 BMA reports extracted from the marrow and clinic medical records were reviewed. Out of 158 adult BMA cytology reports, HMs accounted for 78(49.4%) of all haematological disorders. There was no significant gender difference. The Male 38(48.7%) to Female 40(51.3%) ratio (M:F) was 1:1.1. Their ages ranged from 16 to 85 years with the median age of 54.0 years. Out of the 78 HMs, Lymphoid neoplasms were the most prevalent 47(60.3%), the leukaemias were higher 53/78(67.9%) compared to the non-leukaemic neoplasms. Of the 53 leukaemias, those of chronic lymphoid types were more 24/53(45.3%), followed by the chronic myeloid 15/53(28.3%). Chronic lymphocytic leukaemia (CLL) was the predominant leukaemia 24/53(45.3%) as well as the most prevalent HM 24/78(30.8%), followed by chronic myeloid leukaemia (CML) 19.2%(15/78). Others were myelodysplastic syndrome (MDS) 11.5%(9/78), acute lymphoblastic leukaemia (ALL) 10.3% (8/78), multiple myeloma (MM) 10.3%(8/78), acute myeloblastic leukaemia (AML) 7.7%(6/78), non-Hodgkin's lymphoma (NHL) 6.4%(5/78), Small lymphocytic lymphoma (SLL) 2.6%(2/78) and Hodgkin's lymphoma (HL) 1.3%(1/78). In conclusion, we established high prevalence of HMs among patients who had BMA cytology evaluation at BSUTH with the preponderance of lymphoid malignancies. We advocate for inclusion of HMs in the National Health Insurance Scheme (NHIS) for full implementation and to prioritise provision of modern diagnostic equipment and treatment options for quality and optimal management of leukaemias in the center.
APA, Harvard, Vancouver, ISO, and other styles
10

Sedick, Qanita, Sultan Alotaibi, Saeed Alshieban, Khalid Ben Naheet, and Ghaleb Elyamany. "Natural Killer Cell Lymphoblastic Leukaemia/Lymphoma: Case Report and Review of the Recent Literature." Case Reports in Oncology 10, no. 2 (July 7, 2017): 588–95. http://dx.doi.org/10.1159/000477843.

Full text
Abstract:
Natural killer (NK) cell lymphoblastic leukaemia/lymphoma is a rare haemopoietic tumour currently defined in the 2008 WHO classification under the category of acute leukaemias of ambiguous lineage. A diagnosis of this type of leukaemia is considered in cases expressing CD56 along with immature T-cell-associated markers such as CD2 and CD7 with absence of B-cell and myeloid markers; in addition, blastic plasmacytoid dendritic cell leukaemia should be excluded. Prior to 2008, these precursor NK cell lymphoblastic leukaemias/lymphomas were categorized as myeloid/NK cell acute leukaemia with a phenotype identical to acute myeloid leukaemia with minimal differentiation. While the new classification has merit in having excluded myeloid expression, there is still persistent confusion in the literature and on a practical level with regard to precursor NK cell neoplasms. There is a paucity of recent case reports in the literature after the new WHO classification of this neoplasm. Due to the rarity of this neoplasm, an accurate pathological diagnosis is often difficult. In this article, we describe a case of precursor NK cell lymphoblastic leukaemia/lymphoma presenting with unique morphological features and conflicting immunophenotypes. We also review all case reports of this neoplasm after the WHO 2008 classification.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Acute Leukaemia"

1

Bomken, Simon Nicholas. "Investigating leukaemic propagation in childhood acute lymphoblastic leukaemia." Thesis, University of Newcastle Upon Tyne, 2013. http://hdl.handle.net/10443/1865.

Full text
Abstract:
Childhood acute lymphoblastic leukaemia (ALL) does not possess a propagating cell hierarchy, at least as defined by B-cell precursor immunophenotype. Indeed, many, or even all, leukaemic blasts may have the potential to propagate the disease. This unusual characteristic mirrors the substantial capacity for clonal expansion demonstrated by fully differentiated normal lymphoid cells. This Fellowship aimed to investigate the genetic programmes underlying the propagation of acute lymphoblastic leukaemia. An initial candidate approach confirmed the expression of PIWIL2, a gene critical to the maintenance of germline stem cells, in both cell line and primary ALL. Knockdown of PIWIL2 resulted in reduced cellular proliferation and significant prolongation of doubling time in two ALL cell lines, SEM (MLL/AF4) and 697 (E2A/PBX1). Unexpectedly, PIWIL2 was also found to be expressed in peripheral lymphoid cells from healthy donors, but not terminally differentiated cells of myeloid origin, suggesting that PIWIL2 may have a previously unidentified function in both normal and malignant lymphoid cells. A second project has developed an in vitro genome-wide RNAi screen to identify candidate genes involved in the clonal propagation of ALL. This project has assessed a serial re-plating assay using feeder cell co-culture to provide a surrogate niche environment. Initial results have demonstrated the feasibility of such an approach. The benefit of using a co-culture re-plating assay, as compared to a standard suspension culture approach, remains under investigation. ii Finally, this Fellowship developed a protocol for the lentiviral transduction of patient-derived leukaemic blasts and cloned and validated a novel lentiviral vector capable of in vitro analysis, in vivo disease monitoring and RNAi. With these, it will now be possible to validate candidate leukaemic propagation genes in vivo, using primary leukaemic material. The results of these studies will provide candidates for the development of novel therapeutic agents for children with ALL.
APA, Harvard, Vancouver, ISO, and other styles
2

Bradbury, Dawn Ann. "Factors regulating the autocrine growth of leukaemic cells in acute myeloblastic leukaemia." Thesis, Nottingham Trent University, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.332817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Knapper, Steven. "FLT3 inhibitors in acute myeloid leukaemia." Thesis, University of Oxford, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.432548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Smith, Matthew Liam Walker. "Mutation profiling in acute myeloid leukaemia." Thesis, Queen Mary, University of London, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Quinn, M. F. "Homeobox gene expression in acute leukaemia." Thesis, Queen's University Belfast, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.398094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mannari, Deepak. "The genomics of acute myeloid leukaemia : an investigation into the molecular pathogenesis of acute myeloid leukaemia with t(8;21)." Thesis, Queen Mary, University of London, 2012. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8822.

Full text
Abstract:
Acute myeloid leukaemia is a clonal disorder characterised by recurrent chromosomal translocations. One of the commonest, is the t(8;21) which results in part of the AML1 gene being juxtaposed to most of the ETO gene with the resultant chimeric protein, AML1-ETO, acting predominantly as a transcriptional repressor. Despite the extensive literature available, the exact mechanism by which the chimeric protein results in AML has not been fully elucidated. By using exon arrays and high throughput sequencing as tools it was hoped to gain further insights into the molecular basis of this disease. Gene expression profiling using the exon arrays highlighted molecular pathways and specific genes that play a key role in the pathogenesis in t(8;21). Exon arrays were also used to profile individual exon expression of the ETO gene. This demonstrated that the genomic breakpoint of ETO in the t(8;21) is variable between different patients. This technique also resulted in the discovery of a new exon in the ETO gene. This novel exon results in formation of alternative transcripts of AML1-ETO and was shown in mouse models to play a key role in leukaemogenesis. Chromatin immunoprecipitation followed by high throughput sequencing revealed novel aspects of AML1-ETO binding. A number of novel genes that bind AML1-ETO were recognized and in conjunction with the expression data, a number of hypothesis on how AML1-ETO binding effects gene expression are made.
APA, Harvard, Vancouver, ISO, and other styles
7

Swanepoel, Yolande. "A retrospective study of acute lymphoblastic leukaemia in Paediatric patients at Dr George Mukhari Hospital (2003-2007)." Thesis, University of Limpopo (Medunsa Campus), 2008. http://hdl.handle.net/10386/262.

Full text
Abstract:
Thesis (M Med(Haematology))-- University of Limpopo (Medunsa Campus), 2008.
Introduction: ALL (Acute Lymphoblastic Leukaemia) is the most common leukaemia in childhood. The two most important features predictive of outcome are age and presenting WBC at diagnosis. NCI risk criteria are applied to all children with precursor B-ALL, dividing them into NCI “high risk” (age < 1 year and ≥ 10 yrs, WBC > 50 x 10 9/ ) and NCI “standard risk” (age ≥ 1 year and < 10 yrs, WBC < 50 x 10 9/ ). Gender, immunophenotyping and genetic studies are other features that have been shown to be associated with outcome. Objectives: To determine the correlation between survival outcome of paediatric patients with ALL and different variables, e.g. biological, haematological, immunophenotypic and cytogenetic features at diagnosis, and to determine the duration of survival of a patient since the diagnosis of ALL, at Dr George Mukhari Hospital. Methods: This study was conducted over the period 2003-2007. Children diagnosed with ALL with ages ranging from 1-12 years, were identified. The hospital and laboratory records were analysed retrospectively. Early prognostic features were identified from patient data. Results: Descriptive statistical measures were used to summarize data. Twenty nine paediatric patients with ALL were identified of which 12 were female and 17 were male. The mean age of patients at diagnosis was 7,2 years. The presenting leucocyte count ranged from 2,5 to 325 x 10 9/ . Cytogenetic studies of three patients were available, all of which were unfavourable prognostic factors. Immunophenotyping revealed ten patients with T-cell ALL, 17 patients with B-cell ALL and two patients whose immunophenotype was unknown as recorded results were not available. Twenty one patients’ survival data were known. The longest duration of survival of a patient was 3,7 years. There were seven patients known to be alive at the end of the study period. Conclusion: The cases reported herein and those described in the literature demonstrate the importance of a careful and multidisciplinary approach in the diagnosis and evaluation of paediatric ALL.
APA, Harvard, Vancouver, ISO, and other styles
8

Taussig, David. "Characterisation of acute myeloid leukaemia stem cells." Thesis, Queen Mary, University of London, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cartwright, Cher Suzanne. "Thiopurine Metabolism in Childhood Acute Lymphoblastic Leukaemia." Thesis, University of Sheffield, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.500442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Olwill, Shane. "Annexin II expression in acute myeloid leukaemia." Thesis, University of Ulster, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Acute Leukaemia"

1

Olwill, Shane. Annexin II expression in acute myeloid leukaemia. [S.l: The author], 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barge, A. Acute myeloid leukaemia: The role of haematopoietic growth factors. Macclesfield: Gardner-Caldwell Communications, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Raybould, Simon. Spatial analysis of acute lymphoblastic leukaemia in Tyne and Wear. Newcastle upon Tyne: University of Newcastle upon Tyne Centre for Urban and Regional Development Studies, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Raybould, Simon. Spatial analysis of acute lymphoblastic leukaemia in Tyne and Wear. Newcastle upon Tyne: University of Newcastle upon Tyne Centre for Urban and Regional Development Studies, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Coyne, Rose Mary. A study of erythropoietin levels in children with common acute lymphoblastic leukaemia. [s.1: The Author], 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marwah, Sukhjinder Singh. Role of non-transferrin bound iron in acute leukaemia and sickle cell disease. Wolverhampton: University of Wolverhampton, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Menasce, Lia Patricia. Deletions of the long arm of chromosome 6 in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma. Manchester: University of Manchester, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fitzmaurice, Richard John. Methods for the detection of haemopoietic cells and the assessment of residula haemopoiesis in acute leukaemia. Manchester: University of Manchester, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Acute Leukaemia"

1

Monfardini, S., K. Brunner, D. Crowther, S. Eckhardt, D. Olive, S. Tanneberger, A. Veronesi, J. M. A. Whitehouse, and R. Wittes. "Acute Leukaemia." In Manual of Adult and Paediatric Medical Oncology, 123–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-82489-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

von Wolff, Michael, Nicola Gökbuget, and Andrea Jarisch. "Acute Leukaemia." In Fertility Preservation in Oncological and Non-Oncological Diseases, 55–64. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-47568-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schwab, Claire, and Christine J. Harrison. "Acute Lymphoblastic Leukaemia." In Methods in Molecular Biology, 99–117. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-074-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Willoughby, M. L. N., and B. Lampkin. "Acute Myeloid Leukaemia." In Cancer in Children, 107–21. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84722-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Riehm, H., W. Ebell, H. J. Feickert, and A. Reiter. "Acute Lymphoblastic Leukaemia." In Cancer in Children, 85–106. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84722-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Smith, Matthew L., and Thomas McKerrell. "Acute myeloid leukaemia." In The Genetic Basis of Haematological Cancers, 133–202. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118527948.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Andersson, Anna, Anthony V. Moorman, Christine J. Harrison, and Charles Mullighan. "Acute lymphoblastic leukaemia." In The Genetic Basis of Haematological Cancers, 223–64. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118527948.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Riehm, H., H. J. Feickert, and F. Lampert. "Acute Lymphoblastic Leukaemia." In Cancer in Children, 101–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-96889-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Burnett, Alan K., and David Grimwade. "Acute Myeloid Leukaemia." In Postgraduate Haematology, 352–70. Oxford, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118853771.ch20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Biondi, Andrea, Anna Maria Testi, and Brenda E. S. Gibson. "Acute Promyelocytic Leukaemia." In Molecularly Targeted Therapy for Childhood Cancer, 83–108. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-69062-9_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Acute Leukaemia"

1

Bykowska, K., S. Lapaciuk, M. Janczarski, Z. Wegrzynowicz, and M. Kopec. "PLASMA FIBRONECTIN IN ACUTE LEUKAEMIAS AND DURING STREPTOKINASE THERAPY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643557.

Full text
Abstract:
We have previously shown that digestion of fibronectin (FN) by trypsin, kallikrein and plasmin influences strongly the FN quantitation by electroimmunoassay (EIA) and immunoturbidimetric assay (ITA). Proteolytic degradation led to an overestimation of FN by EIA but to a decline of results in ITA (Thromb.Haemostas., 53:377, 1985). In this study plasma FN was determined in parallel by EIA and ITA in adult patients with acute leukaemia prior to chemotherapy and in patients treated with SK for DVT. It has been assumed that in leukaemias leukocytic proteases can degrade FN. In 24 control subjects, mean values of plasma FN determined by EIA (285 ± 61 mg/1) and by ITA (268 ± 61 mg/1) did not differ. In contrast, significantly higher values were found by EIA (268 ± 100 mg/1) than by ITA ( 214 ± 65 mg/1, p < 0.01) in 38 patients with acute myeloid leukaemia (AML) and in 12 with blast crisis (BC) in chronic granulocytic leukaemia (245±73 mg/1 and 182 ± 46 mg/1 respectively, p < 0.05). Difference in results of two assays in 10 patients with acute lymphoblastic leukaemia (ALL) was not significant. A decrease in plasma FN when compared with controls was detected only by ITA but not by EIA in AML and BC (p < 0.001). The results of two immunoassays showed a high correlation in control group (r = 0.940) and in ALL (r = 0.838), lower in BC (r = 0.570) and poor in AML (r = 0.163). Discrepant were also results of parallel FN determination by EIA ai]dTJTA in 4 patients treated with SK. Higher values of EIA than of ITA could indicate plasmin mediated FN proteolysis. We have not confirmed recent reports on a frequent occurrence in leukaemias of slowly migrating peak of plasma FN complexes in two-dimensional crossed Immunoelectrophoresis. Such peaks were detected in only 3 of the 46 examined plasma samples. In conclusion the parallel FN determination by EIA and ITA can provide an ’ indirect evidence for the occurrence of proteolytic degradation of plasma FN in vivo.
APA, Harvard, Vancouver, ISO, and other styles
2

Tirtakusuma, RF, S. Bomken, and O. Heidenreich. "Control of Lineage Commitment in Acute Leukaemia." In 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1602223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Armenteros-Monterroso, E., L. Zhao, J. de Boer, and O. Williams. "Investigating Reptin function in Acute Myeloid Leukaemia." In 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1602188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Negi, Amit, Jyoti Rawat, Chirag Gupta, Swapnil Joshi, and Mansi Pathak. "Ensemble CAD System for Acute Lymphoblastic Leukaemia Classification." In 2022 3rd International Conference on Intelligent Engineering and Management (ICIEM). IEEE, 2022. http://dx.doi.org/10.1109/iciem54221.2022.9853051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wilde, J. T., S. Kitchen, F. E. Freston, and M. Greaves. "A COMPARISON OF D-DIMER AND SERUM FIBRINOGEN/FIBRIN DEGRADATION PRODUCT LEVELS (F.D.P.’s) IN THE INVESTIGATION OF HYPERCOAGULABLE STATES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643138.

Full text
Abstract:
D-Dimer assays measure specific breakdown products of crosslinked fibrin whereas FDP assays are not specific for these products. We have, therefore, measured D-Dimer levels (MabCo Dimer Test) semi-quantitatively in patients with clinical and laboratory evidence of disseminated intravascular coagulation, acute and chronic liver disease, acute leukaemia at presentation and acute venous thrombosis at diagnosis. We have also measured D-Dimer in the 3rd trimester of normal pregnancy and in pregnancies with complications. We compared these levels with F.D.P. levels measured by the Thrombo-Wellcotest. Patients with liver disease comprised mainly cirrhosis and acute viral hepatitis; those with venous thrombosis had this diagnosis confirmed by venography. Pregnancy complications included mainly pre-eclampsia, ante-partum haemorrhage and intra-uterine foetal death. D-Dimer levels were elevated ( 200ng/ml) in all 31 patients with D.I.C., in 34 of 40 with liver disease, in 13 of 16 with acute leukaemia, in all 10 patients with D.V.T., in 9 of 16 normal pregnancies and in 29 of 39 complicated pregnancies. Using a rank correlation method, there was correlation between D-Dimer and F.D.P. levels (Normal 8ug/ml) in the following groups of patients as follows (r is the correlation coefficient, levels of significance are shown in brackets):D.I.C. r=0.72(0.2%), liver disease r=0.56(0.2%), acute leukaemia r=0.72(0.2%), D.V.T. r=0.83(1%) and complicated pregnancy r=0.42(1)6). There was no correlation between D-Dimer and F.D.P. levels in normal pregnancy. Very rarely were D-Dimer levels elevated when F.D.P. levels were normal and vice-versa. We conclude that a close relationship does exist between D-Dimer and F.D.P. levels in the clinical conditions that we have studied. We note the high incidence of elevated D-Dimer levels and the close correlation with F.D.P. levels in patients with liver disease and the high incidence of elevated D-Dimer levels suggesting increased activity of the coagulation system in patients with acute leukaemia.
APA, Harvard, Vancouver, ISO, and other styles
6

Mitel, Alina, Carmen Burloiu, Alexandru Capisizu, and Monica Luminos. "P137 Case presentation: diagnostic difficulties in acute lymphoblastic leukaemia." In 8th Europaediatrics Congress jointly held with, The 13th National Congress of Romanian Pediatrics Society, 7–10 June 2017, Palace of Parliament, Romania, Paediatrics building bridges across Europe. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313273.225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pal, D., H. Blair, S. Boyd, P. Bakelis, A. Elder, S. Moorthy, J. Vormoor, and O. Heidenreich. "The human bone marrow (BM) niche in acute leukaemia." In 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1602218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Clesham, KJ, L. Gasparoli, C. Virely, S. Cantilena, J. De Boer, and O. Williams. "Targeting c-MYB in Acute Leukaemia through Drug Repositioning." In 32. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1687158.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Skelding, K., J. Gilchrist, E. Pearsall, M. Chi, N. Bowden, and L. Lincz. "PO-144 Role of increased expression of brain and acute leukaemia, cytoplasmic (BAALC) in acute myeloid leukaemia (AML) DNA damage repair pathways." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Innes, A., T. Barrow, E. Schwalbe, L. Fadhel, and S. Gordon. "PO-139 Investigating unusual synthetic lethalgenes in acute lymphoblastic leukaemia." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Acute Leukaemia' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography